Quetiapine augmentation of serotonin reuptake inhibitors in obsessive - Compulsive disorder

N. Mohr, B. Vythilingum, R. A. Emsley, D. J. Stein

Research output: Contribution to journalArticlepeer-review

75 Scopus citations


The augmentation of serotonin reuptake inhibitors (SRIs) with atypical antipsychotics for the management of treatment-resistant obsessive-compulsive disorder (OCD) is gaining increasing acceptance. Quetiapine is a novel antipsychotic which is well tolerated, and which may therefore be particularly useful in this context. Charts of all patients treated in our OCD clinic with the combination of an SRI and quetiapine were reviewed. Demographic details and clinical symptoms on the Yale-Brown Obsessive-Compulsive Scale and the Clinical Global Impressions Scale (CGI) were tabulated before and after augmentation. Eight OCD patients who had proven resistance to treatment with SRIs had received quetiapine augmentation. Four of these eight patients were responders (CGI of 1 or 2) within 4 weeks. In the treatment-responders, the medication was well tolerated. Although limited by the retrospective design and lack of controls, these data are consistent with the growing literature suggesting that approximately one-half of OCD patients resistant to treatment with SRIs may respond to augmentation with an atypical antipsychotic. Quetiapine, a relatively well tolerated agent, deserves further controlled study in this context.

Original languageEnglish
Pages (from-to)37-40
Number of pages4
JournalInternational Clinical Psychopharmacology
Issue number1
StatePublished - 2002
Externally publishedYes


  • Dopamine
  • Obsessive-compulsive disorder
  • Quetiapine
  • Serotonin reuptake inhibitors


Dive into the research topics of 'Quetiapine augmentation of serotonin reuptake inhibitors in obsessive - Compulsive disorder'. Together they form a unique fingerprint.

Cite this